IELSG 34: A Multicenter Phase II study to evaluate the clinical activity and the safety profile of everolimus (RAD001) in marginal zone B-cell lymphomas (MZL) EudraCT Number 2009-011725-14.
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2014
At a glance
- Drugs Everolimus (Primary)
- Indications B cell lymphoma
- Focus Therapeutic Use
- 08 May 2012 Planned end date 1 Apr 2013 added as reported by ClinicalTrials.gov.
- 08 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Mar 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.